Compare Incyte Corporation (INCY) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ArcelorMittal SA — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.99B), while ArcelorMittal SA trades at $61.32 (market cap $47.06B). The key difference: ArcelorMittal SA is far larger — about 2× Incyte Corporation's market cap, and ArcelorMittal SA pays a 0.96% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and ArcelorMittal SA for 36 Days on average.
| INCY | MT | |
|---|---|---|
Market Cap | $22.99B | $47.06B |
Volume | 1,274,487 | 1,545,197 |
Sector | Health | Basic Materials |
52-Week High | $129.93 | $78.74 |
52-Week Low | $83.80 | $36.91 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $18.50B | $56.63B |
Dividend Yield | — | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $112.75, up 0.02% on the day, with a bullish technical signal from oscillators but bearish moving averages. The company reported strong Q2 2026 earnings, beating expectations with EPS of $3.09 versus $2.15, and revenue growth from $5.14B in 2025 to a projected $5.8B in 2026. Recent FDA approval for Atebrioz and a strategic push for post-JAKAFI growth highlight pipeline progress. Valuation ratios appear reasonable with a P/E of 14.45 and EV/EBITDA of 8.94.
Outlook is positive with a consensus price target of $132.07, implying 17% upside, supported by 52% analyst buy ratings. Risks include reliance on JAKAFI, which loses exclusivity after 2029, and near-term earnings volatility as seen in the Q4 2025 miss. Strong cash flow and profitability metrics suggest resilience, but execution on pipeline diversification is critical for sustained growth.
ArcelorMittal (MT) trades at $61.30, down 5.97% amid bearish technical signals and recent Ukraine plant impairment concerns. The stock shows mixed fundamentals with attractive valuation metrics (P/S 0.76, P/B 0.86) but declining revenue trends from $79.8B in 2022 to $61.4B in 2025. Recent Q2 2026 earnings missed expectations, though management expects stronger second-half performance supported by European demand recovery and strategic investments.
While analyst consensus remains bullish with a $74.33 price target (52% buy ratings), significant risks include ongoing Ukraine operations disruption, $1B impairment charge, and China demand weakness. The current price near support levels presents potential entry point for value investors, but requires careful monitoring of European recovery execution and geopolitical stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
